Taiwan's digital health company H2U has raised more than $10m in its Series B fundraising round to boost its digital health initiatives. 

The round saw participation from companies across various sectors, including Seoul Clinical Laboratories (SCL) from South Korea, Taiwan's Standard Foods, Leadgene Biomedical, and GrandTech CG Systems, a representative of Amazon Web Services (AWS).  

Before the Series B fundraise, H2U had already garnered support from institutional investors such as WeLeader Bio, Foxconn Technology, TOPCO, UDN, ADATA, Wondercise, Sparklabs and Flight International.  

Established in 2013, H2U offers AI technology that provides valuable insights into member behaviour and health needs, supporting the creation of holistic solutions for a healthy lifestyle.  

Since its inception, H2U has amassed more than three million platform members and integrated services like H2U eXpert, Everyday Health, H2U eXamine, Sports Note, and iFit. 

Leveraging the support from its new strategic investment partners, the Taiwanese digital healthcare company aims to strengthen its capabilities in AI data insights and product promotion. 

The influx of funds will also provide a stable backing for H2U's research and development efforts, particularly in the realm of AI-driven data analysis and the promotion of its digital health ecosystem platform ‘H2U pano’. 

H2U pano provides digital health management, precise nutrition science, individualised sports prescriptions, personalised medical checkups, and corporate health promotion.  

Looking ahead, H2U is set to establish its international presence in 2024, starting with the South Korean medical market through a collaboration with the SCL Group in the first half of the year.  

The company plans to introduce a software-as-a-service (SaaS)-based digital health check platform and a comprehensive health management programme across various medical examination centres in South Korea.  

Using SCL's established business presence in Northeast and Southeast Asia, H2U further aims to participate in major international medical events, including Medica Germany, CES, and the J P Morgan Healthcare Conference in the US. 

H2U is also preparing for an initial public offering (IPO) by the end of the year, which is expected to provide more capital to support its technological research and development initiatives.